CN108135877B - 药物共晶及其用途 - Google Patents

药物共晶及其用途 Download PDF

Info

Publication number
CN108135877B
CN108135877B CN201680028846.3A CN201680028846A CN108135877B CN 108135877 B CN108135877 B CN 108135877B CN 201680028846 A CN201680028846 A CN 201680028846A CN 108135877 B CN108135877 B CN 108135877B
Authority
CN
China
Prior art keywords
cancer
crystal
cbcbp
virus
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680028846.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN108135877A (zh
Inventor
刘晓忠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syn Nat Products Enterprise LLC
Original Assignee
Syn Nat Products Enterprise LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syn Nat Products Enterprise LLC filed Critical Syn Nat Products Enterprise LLC
Publication of CN108135877A publication Critical patent/CN108135877A/zh
Application granted granted Critical
Publication of CN108135877B publication Critical patent/CN108135877B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201680028846.3A 2015-05-18 2016-05-17 药物共晶及其用途 Active CN108135877B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562163256P 2015-05-18 2015-05-18
US62/163,256 2015-05-18
PCT/US2016/032856 WO2016187191A1 (en) 2015-05-18 2016-05-17 A pharmaceutical co-crystal and use thereof

Publications (2)

Publication Number Publication Date
CN108135877A CN108135877A (zh) 2018-06-08
CN108135877B true CN108135877B (zh) 2021-04-13

Family

ID=57320544

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680028846.3A Active CN108135877B (zh) 2015-05-18 2016-05-17 药物共晶及其用途

Country Status (9)

Country Link
US (1) US10751318B2 (enExample)
EP (1) EP3297624B1 (enExample)
JP (1) JP6851989B2 (enExample)
KR (1) KR20180008594A (enExample)
CN (1) CN108135877B (enExample)
AU (1) AU2016265922B2 (enExample)
BR (1) BR112017024727A2 (enExample)
CA (1) CA2986136A1 (enExample)
WO (1) WO2016187191A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180008594A (ko) 2015-05-18 2018-01-24 신-낫 프로덕츠 엔터프라이즈 엘엘씨 약제학적 공-결정 및 그의 용도
JP6768716B2 (ja) 2015-06-19 2020-10-14 シン−ナット プロダクツ エンタープライズ エルエルシー カルボプラチンベースの共結晶の医薬組成物及びその用途
EP3297440A4 (en) 2015-06-19 2019-04-10 Syn-Nat Products Enterprise LLC COMPOSITION WITH CARBOPLATIN AND USE
KR20180021805A (ko) 2015-06-25 2018-03-05 신-낫 프로덕츠 엔터프라이즈 엘엘씨 약제학적 공-결정 조성물 및 이의 용도
CN109053808B (zh) * 2017-06-21 2020-12-29 宋勤华 一种高纯度双环铂针状晶体的工业化制备方法
MX2020005310A (es) * 2017-11-21 2020-10-08 Medoncare Pharmaceutical Co Ltd Producto de combinacion que comprende dicicloplatino y metodo de preparacion y uso del mismo.
CN116217628B (zh) * 2023-05-08 2023-07-14 华东理工常熟研究院有限公司 奥沙利铂Pt(IV)配合物的共晶及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101389637A (zh) * 2006-01-30 2009-03-18 普拉托技术（私有）公司 铂(ⅱ)配合物的制备

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3290365A (en) * 1963-06-21 1966-12-06 Standard Oil Co Method of preparing cis-cyclobutane-1, 2-dicarboxylic acid
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
KR100317473B1 (ko) 1999-05-11 2001-12-22 이계호 신규의 백금(ｉｖ)착제 및 그 제조방법
CN1121380C (zh) * 2000-03-03 2003-09-17 北京兴大豪斯科技有限公司 一种抗肿瘤的双二羧酸二氨络铂衍生物及其药物组合物
AUPQ641100A0 (en) 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
US7259270B2 (en) 2001-11-30 2007-08-21 Jingzun Wang Supermolecular carboplatin derivatives, their preparation and pharmaceutical composition containing them as active ingredient and applications of the compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
IL163846A0 (en) * 2002-03-01 2005-12-18 Univ South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
EA200500234A1 (ru) 2002-08-19 2005-08-25 Пфайзер Продактс Инк. Комбинированная терапия гиперпролиферативных болезней
WO2004099224A1 (de) 2003-05-05 2004-11-18 Universität Regensburg Carboplatin-artige platin (ii)- komplexe
EP1845974A1 (en) 2005-01-21 2007-10-24 Astex Therapeutics Limited Pharmaceutical compounds
JP2009545601A (ja) 2006-08-02 2009-12-24 サネシス ファーマシューティカルズ， インコーポレイテッド （＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の組合せ使用
BRPI0913485A2 (pt) 2008-09-15 2016-06-07 Kasina Laila Innova Pharmaceuticals Private Ltd medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres.
CZ302618B6 (cs) * 2009-09-10 2011-08-03 Univerzita Palackého Cyklobutan-1,1-dikarboxylátokomplexy platiny s deriváty N6-benzyladeninu, zpusoby jejich prípravy a použití techto komplexu jako léciv v protinádorové terapii
US20110287110A1 (en) 2010-04-23 2011-11-24 Mark Wesley Dewhirst Combination cancer treatment
KR102411227B1 (ko) 2013-10-17 2022-06-21 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
CN107530309A (zh) 2015-04-22 2018-01-02 新纳特产品公司 共晶组合物及其药物用途
KR20180008594A (ko) 2015-05-18 2018-01-24 신-낫 프로덕츠 엔터프라이즈 엘엘씨 약제학적 공-결정 및 그의 용도
JP6768716B2 (ja) 2015-06-19 2020-10-14 シン−ナット プロダクツ エンタープライズ エルエルシー カルボプラチンベースの共結晶の医薬組成物及びその用途
EP3297440A4 (en) 2015-06-19 2019-04-10 Syn-Nat Products Enterprise LLC COMPOSITION WITH CARBOPLATIN AND USE
KR20180021805A (ko) * 2015-06-25 2018-03-05 신-낫 프로덕츠 엔터프라이즈 엘엘씨 약제학적 공-결정 조성물 및 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101389637A (zh) * 2006-01-30 2009-03-18 普拉托技术（私有）公司 铂(ⅱ)配合物的制备

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
W.E. HILL等.SYNTHESIS, CHARACTERIZATION AND ANTI-TUMOUR TESTING OF SOME PLATINUM(II) AMINE COMPLEXES CONTAINING 1,1- AND 1,2.CYCLOBUTANEDICARBOXYLATE LIGANDS.《Chem.-BioL Interactions》.1990,第73卷337-351. *
Xuqing Yang等.Determination methods for the anticancer drug dicycloplatin, a supramolecule assembled through hydrogen bonding.《Analyst》.2015,第140卷第2704–2712页. *

Also Published As

Publication number Publication date
BR112017024727A2 (pt) 2018-07-31
AU2016265922A1 (en) 2017-12-07
AU2016265922B2 (en) 2021-05-20
KR20180008594A (ko) 2018-01-24
EP3297624A1 (en) 2018-03-28
EP3297624B1 (en) 2021-03-03
JP6851989B2 (ja) 2021-03-31
US10751318B2 (en) 2020-08-25
CA2986136A1 (en) 2016-11-24
CN108135877A (zh) 2018-06-08
EP3297624A4 (en) 2018-12-05
JP2018521969A (ja) 2018-08-09
WO2016187191A1 (en) 2016-11-24
US20180289662A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
US11685757B2 (en) Pharmaceutical co-crystal composition and use thereof
US10751318B2 (en) Pharmaceutical co-crystal and use thereof
DK2547334T3 (en) NEW CONNECTIONS AND COMPOSITIONS FOR TARGETING CANCER STAM CELLS
DK3108750T3 (en) NEW RELATIONS AND COMPOSITIONS TARGETED FOR CANCER STAM CELLS
CN110092775B (zh) 靶向cdk4/6激酶抑制剂的晶型
CN107847508B (zh) 基于卡铂的共晶的药物组合物及其用途
WO2013011841A1 (ja) 悪性腫瘍に対する高選択的細胞毒性を有するインディルビン誘導体
WO2022089590A1 (zh) 黄酮苷-有机胺类酪氨酸激酶抑制剂复盐化合物及其制备方法和应用
JP2015531355A (ja) 腫瘍治療のための薬剤組成物及びその適用
CN106995368B (zh) 一种非atp竞争性fgfr1抑制剂及其应用
WO2015027669A2 (zh) 苯基取代化合物及其药物组合物和应用
RU2784809C2 (ru) Комбинированный продукт, содержащий дициклоплатин, и способ его получения и применения
WO2014138507A1 (en) Treatment of cervical cancer and/or ovarian cancer using a transcription factor modulator

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant